About Innoplexus
Innoplexus is a company based in Eschborn (Germany) founded in 2011 by Gunjan Bhardwaj. Innoplexus offers products and services including Ontosight Platform, Amrit Ecosystem, Search & Explore, and Dashboards. Innoplexus operates in a competitive market with competitors including Merck, Roivant Sciences, Gilead, IQVIA and Lilly, among others.
- Headquarter Eschborn, Germany
- Founders Gunjan Bhardwaj
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Innoplexus Ag
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
EOS VC
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Innoplexus
Innoplexus offers a comprehensive portfolio of products and services, including Ontosight Platform, Amrit Ecosystem, Search & Explore, and Dashboards.
Platform for aggregating and analyzing biomedical data for drug discovery.
Enables AI and blockchain for equitable healthcare data exchange.
Tool for searching and synthesizing global biomedical information.
Provides data visualization for decision-making in clinical and regulatory affairs.
People of Innoplexus
Unlock access to complete
Unlock access to complete
Funding Insights of Innoplexus
Investors in Innoplexus
Innoplexus has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include EOS VC and HCS Beteiligungsgesellschaft.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is provided to blockchain startups by EOS VC.
|
Locked | Locked | Locked | |
|
Multiple sectors are invested in by the venture capital firm.
|
Locked | Locked | Locked |
Investor details for Innoplexus
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Innoplexus
Investment portfolio details for Innoplexus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Innoplexus
Detailed financials for Innoplexus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Innoplexus Comparisons
Peer comparison for Innoplexus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Innoplexus
Innoplexus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, Gilead, IQVIA and Lilly, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Clinical research and commercialization solutions are provided for healthcare.
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Cloud-based data management solutions for healthcare are provided.
|
Detailed competitors of Innoplexus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Innoplexus
Complete news archive for Innoplexus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Innoplexus
Innoplexus was founded in 2011 and raised its 1st funding round 5 years after it was founded.
Innoplexus is headquartered in Eschborn, Germany. It is registered at Eschborn, Hesse, Germany.
Gunjan Bhardwaj is the current CEO of Innoplexus. They have also founded this company.
Innoplexus was founded in 2011 and is headquartered in Eschborn, Germany. Operations focus on the life sciences sector, where AI-driven tools are utilized to support drug discovery and development processes. The proprietary ontosight AI search platform is employed to analyze data and identify potential for safer, more effective medicines. Services are extended to pharmaceutical and biotech entities seeking enhanced research efficiency.
Innoplexus's top competitors include Merck, Roivant Sciences and AbbVie.
Innoplexus offers Ontosight Platform, Amrit Ecosystem, Search & Explore, and Dashboards.
Innoplexus has 2 investors. Key investors include EOS VC, and HCS Beteiligungsgesellschaft.